Prof. Dr. Paul-Georg Germann

Strategically and content wise leading a global unit for Chemical and Preclinical Safety with 126 FTE, covering Preclinical Safety Assessment for all Aspects of Chemical and Preclinical Safety in the indication fields of Oncology, Immunooncology and Immunology. Chemical Safety Assessments for high performance materials with respect to ecotoxicology and REACH.

Vice President New Frontier Science Europe Takeda Pharmaceuticals, September 2012 – Present, Europe Scope of New Frontier Science: Bring very early science and groundbreaking innovation from academia and start ups into the value stream of a large pharmaceutical company. Create value through leveraging international connections within the academic community. Looking for platform technologies, focused therapies or healthcare concepts.

01.12.2007-30.09.2012: Vice President “Discovery to Proof of Concept Development” Organisation, Nycomed a Takeda Company, Constance, Germany (Lead of R&D organisation with 5 multinational sites (Germany, Denmark, India) and approx. 450 employees, annual budget responsibility: 80 Mio.€; 01.03.2007-30.11.2007: Managing director and Vice President of “In vivo Efficacy & Safety”, 73 colleagues from pharmacology department in Constance reporting directly to Prof. Dr. Germann (approx. 220 employees in total).

Toxicology and Risk Assessment

Pathology Toxicological Pathology Tumor and cell differentiation